Furthermore, we identified an association between karyotype abnormalities and TP53 mutations, with poorer outcomes in CMML patients; however, these associations were only significant for RUNX1 and TP53 in multivariate analysis. This evidence concerns the gene TP53 and chronic myelomonocytic leukemia.